220 related articles for article (PubMed ID: 7475042)
1. Effects of KRN4884, a novel K channel opener, on the cardiovascular system in anesthetized dogs: a comparison with levcromakalim, nilvadipine, and nifedipine.
Izumi H; Jinno Y; Kaneta S; Tanaka Y; Okada Y; Izawa T; Ogawa N
J Cardiovasc Pharmacol; 1995 Aug; 26(2):189-97. PubMed ID: 7475042
[TBL] [Abstract][Full Text] [Related]
2. Effects of the potassium channel openers KRN4884 and levcromakalim on the contraction of rat aorta induced by A23187, compared with nifedipine.
Kawahara J; Izumi H; Okada Y; Izawa T
Naunyn Schmiedebergs Arch Pharmacol; 1996 Oct; 354(4):460-5. PubMed ID: 8897449
[TBL] [Abstract][Full Text] [Related]
3. KRN4884, a novel K channel opener: antihypertensive effects in conscious renal hypertensive dogs.
Kawahara J; Jinno Y; Endo M; Izumi H; Takeuchi A; Izawa T
J Cardiovasc Pharmacol; 1997 Jun; 29(6):814-9. PubMed ID: 9234664
[TBL] [Abstract][Full Text] [Related]
4. Effects of KRN4884 (a novel K+ channel opener), levcromakalim, nilvadipine and propranolol on endothelin-1-induced heart disorders in anesthetized rats.
Harada K; Kawahara J; Okada Y; Uzumaki H; Kusaka M; Tokiwa T
Jpn J Pharmacol; 1998 Nov; 78(3):261-8. PubMed ID: 9869259
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive properties of KRN4884, a novel long-lasting potassium channel opener.
Kawahara J; Kashiwabara T; Ogawa N; Okada Y; Izawa T
J Cardiovasc Pharmacol; 1999 Feb; 33(2):292-4. PubMed ID: 10028939
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo vasodilating effects of KRN4884, Ki1769 and Ki3005, pyridinecarboxamidine derivatives.
Izumi H; Kawahara J; Takeuchi A; Izawa T; Ogawa N
Fundam Clin Pharmacol; 1997; 11(6):561-6. PubMed ID: 9444524
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular effects of the novel potassium channel opener UR-8225.
Tamargo J; Pérez O; Delpón E; García-Rafanell J; Gómez L; Cavalcanti F
J Cardiovasc Pharmacol; 1995 Aug; 26(2):295-305. PubMed ID: 7475055
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of vasodilator effects of the potassium channel openers NIP-121 and levcromakalim in dogs and rats.
Yamashita T; Masuda Y; Kawamura N; Fujikura N; Tanaka S
Jpn J Pharmacol; 1995 Jun; 68(2):145-52. PubMed ID: 7563971
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic profiles of YM934, a novel potassium channel opener.
Uchida W; Masuda N; Taguchi T; Shibasaki K; Shirai Y; Asano M; Matsumoto Y; Tsuzuki R; Fujikura T; Takenaka T
J Cardiovasc Pharmacol; 1994 Feb; 23(2):180-7. PubMed ID: 7511745
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of KRN2391 in anesthetized dogs: a comparison with cromakalim and nitroglycerin.
Kaneta S; Yokoyama T; Izumi H; Izawa T; Ogawa N
Arch Int Pharmacodyn Ther; 1994; 327(2):184-93. PubMed ID: 7979827
[TBL] [Abstract][Full Text] [Related]
11. Potassium channel-opening and vasorelaxant profiles of a novel compound YM099 in rat isolated portal vein and rabbit isolated aorta.
Uchida W; Hirano Y; Shirai Y; Taguchi T; Masuda N; Shibasaki K; Hirano S; Matsumoto Y; Tsuzuki R; Yanagisawa I
Arch Int Pharmacodyn Ther; 1994; 327(3):330-43. PubMed ID: 7848015
[TBL] [Abstract][Full Text] [Related]
12. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
[TBL] [Abstract][Full Text] [Related]
13. Effects of rubidium on responses to potassium channel openers in rat isolated aorta.
Greenwood IA; Weston AH
Br J Pharmacol; 1993 Aug; 109(4):925-32. PubMed ID: 8401946
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship of a novel K+ channel opener, KRN4884, and related compounds in porcine coronary artery.
Izumi H; Tanaka Y; Okada Y; Ogawa N; Izawa T
Gen Pharmacol; 1996 Sep; 27(6):985-9. PubMed ID: 8909979
[TBL] [Abstract][Full Text] [Related]
15. Comparison of coronary dilating effects of Ki1769, a new K channel opener of the pyridinecarboximidamide type, and nifedipine in anesthetized dogs.
Yokoyama T; Kaneta S; Miwa A; Tanaka Y; Izumi H; Izawa T; Ogawa N
Arch Int Pharmacodyn Ther; 1994; 327(2):194-203. PubMed ID: 7979828
[TBL] [Abstract][Full Text] [Related]
16. Ba2+ differentially inhibits the Rb+ efflux promoting and the vasorelaxant effects of levcromakalim and minoxidil sulfate in rat isolated aorta.
Quast U; Baumlin Y; Loffler C
Naunyn Schmiedebergs Arch Pharmacol; 1995 Dec; 353(1):86-93. PubMed ID: 8750921
[TBL] [Abstract][Full Text] [Related]
17. Effect of KRN2391 on venous return: comparison with other vasodilators.
Kaneta S; Jinno Y; Miwa A; Fukushima H; Ogawa N
J Cardiovasc Pharmacol; 1993 Jul; 22(1):82-8. PubMed ID: 7690101
[TBL] [Abstract][Full Text] [Related]
18. Effects of chronic oral administration of levcromakalim on in vitro contractile responses of arterial smooth muscle.
Trongvanichnam K; Mitsui-Saito M; Ozaki H; Karaki H
Eur J Pharmacol; 1996 May; 303(1-2):39-45. PubMed ID: 8804909
[TBL] [Abstract][Full Text] [Related]
19. Effect of an ATP sensitive potassium channel opener, levcromakalim, on coronary arterial microvessels in the beating canine heart.
Sato K; Kanatsuka H; Sekiguchi N; Akai K; Wang Y; Sugimura A; Kumagai T; Komaru T; Shirato K
Cardiovasc Res; 1994 Dec; 28(12):1780-6. PubMed ID: 7867030
[TBL] [Abstract][Full Text] [Related]
20. Analysis of relaxation and repolarization mechanisms of nicorandil in rat mesenteric artery.
Fujiwara T; Angus JA
Br J Pharmacol; 1996 Dec; 119(8):1549-56. PubMed ID: 8982500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
